title: Toxicokinetic evaluation of a selegiline transdermal system in the dog.
abstract: The toxicology and toxicokinetics of a selegiline transdermal system (STS) were evaluated in a 3 month dog study of daily 24 h applications of placebo 4, 8, or 12 STSs in 32 male and 32 female beagle dogs. Each STS delivered approximately 5 mg selegiline over 24 h. No drug-related signs of toxicity were noted in any group with respect to clinical observations, dermal effects, body weight, food consumption, hematology, urinalysis data, or ophthalmoscopic or electrocardiographic examinations. Clinical chemistry data revealed no consistent adverse effects except for an increase in alanine aminotransferase in dogs receiving 8 and 12 STSs. Histological evaluation of tissues revealed the presence of pigment in the Kupffer cells of dogs treated with 8 and 12 STSs. There were no pathology findings suggestive of hemolysis or cholestasis. The no-effect level (NOEL) was 4 STSs (2.9 mg kg-1 d-1). There were no degenerative or life-threatening toxic effects up to 12 STSs (8.5 mg kg-1 d-1). Gender-related differences in steady-state plasma levels were not observed. Steady-state plasma concentrations were similar to maximum plasma concentrations obtained in single-dose studies, suggesting that drug accumulation was not evident. Simulation of systemic exposure following oral administration of 16.8 mg kg-1 d-1 from previous toxicology studies indicated that selegiline exposure following 12 STSs is sixfold greater while N-desmethylselegiline, L-amphetamine, and L-methamphetamine exposure is 0.5, 0.15, and 0.14 times the exposure in the oral study. The threefold difference in NOEL between oral and transdermal studies in the dog (0.8 versus 2.9 mg kg-1 d-1) is probably related to greater L-amphetamine and L-methamphetamine exposure following oral administration. The reduction in metabolite formation, relative exposure of selegiline in the dog at the NOEL compared to oral toxicology studies, and margin of safety provided, given that the expected clinical dose is less than the dosage of oral Eldepryl (0.15 mg kg-1 d-1), documents the safety of the selegiline drug substance and indicates that additional toxicologic findings with the STS may not be expected.
authors.affiliation: Somerset Pharmaceuticals, Tampa, FL, USA. jsb@somersetpharm.com
authors.forename: J S
authors.initials: JS
authors.lastname: Barrett
authors.forename: A R
authors.initials: AR
authors.lastname: DiSanto
authors.forename: P J
authors.initials: PJ
authors.lastname: Thomford
authors.forename: E M
authors.initials: EM
authors.lastname: Larsen
authors.forename: M J
authors.initials: MJ
authors.lastname: Palazzolo
authors.forename: R J
authors.initials: RJ
authors.lastname: Morales
mesh_terms: D000279:Administration, Cutaneous; D000818:Animals; D000978:Antiparkinson Agents / Q000493:pharmacokinetics / Q000633:toxicity*; D004285:Dogs; D016503:Drug Delivery Systems; D004353:Drug Evaluation, Preclinical; D005260:Female; D008297:Male; D008996:Monoamine Oxidase Inhibitors / Q000493:pharmacokinetics / Q000633:toxicity*; D010865:Pilot Projects; D012642:Selegiline / Q000493:pharmacokinetics / Q000633:toxicity*
chemical_list: D000978:Antiparkinson Agents; D008996:Monoamine Oxidase Inhibitors; D012642:Selegiline